PIPR
Piper Sandler Companies
NYSE · Financial Services · Financial - Capital Markets · US
$77.05
−0.89%Aug 14, 2026, 14:05 UTC
Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Source:Aug 11, 2026, 05:21 UTC
Zoetis Inc.'s stock price hit a new 52-week low during mid-day trading on Monday after Piper Sandler lowered its price target from $90.00 to $80.00.
Source:Aug 6, 2026, 07:14 UTC
Twist Bioscience's share price rose 10.3% during mid-day trading on Wednesday after Piper Sandler raised its price target.
Source:Jul 30, 2026, 12:00 UTC
Piper Sandler Companies reported its second quarter 2026 financial results on July 30, 2026.
Jul 27, 2026, 20:30 UTC
Bluestone Investment Partners made an investment in Delphinus Engineering, with terms undisclosed.
Source:Jul 14, 2026, 15:48 UTC
SK Hynix ADR options began trading on US options exchanges, with over 33,000 contracts traded by early afternoon, and the ADR rose over 17% during the session.
Source:Jun 29, 2026, 13:00 UTC
Piper Sandler Companies added John D'Amico as a managing director in its restructuring group.
Source:Jun 23, 2026, 19:45 UTC
Berkshire Partners has agreed to make a strategic investment in Harbourfront Wealth Group, valuing the firm at C$1.775 billion.
Source:Jun 4, 2026, 10:34 UTC
CereVasc, Inc. completed an $85 million Series C financing led by Piper Sandler Merchant Banking with participation from Johnson & Johnson Innovation – JJDC, Inc., Medtronic, and existing investors.
Source: